Skip to main content

Table 1 Clinical and molecular characteristics of patients with pediatric acute T-ALL with respect to BRD4 expression

From: BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

 

High BRD4 expression

Low BRD4 expression

P-Value

Gender, n (%)

  

0.409

 Male

26 (57)

12 (26)

 

 Female

7 (15)

1 (2)

 

Age at diagnosis,years,median (range)

7.6 (2.3–11.6)

7.9 (1.2–12.2)

0.232

Hemoglobin, g/L, median (range)

102 (54–152)

105 (49–115)

0.518

Platelet, (× 109/L), median (range)

78 (10–263)

65 (30–206)

0.634

Initial BM blast (%)

87 (24–100)

92 (71–97)

0.191

Initial WBC, (× 109/L), n (%)

  

1.000

 < 100

14 (31)

5 (11)

 

 ≥ 100

19 (4)

8 (17)

 

Prednisone Response, n (%)

  

0.738

 Good

12 (26)

6 (13)

 

 Poor

21 (46)

7 (15)

 

Day 15th BM, n (%)

  

0.675

 M1 + M2

20 (43)

7 (15)

 

 M3

13 (28)

6 (14)

 

D33th BM blast, n (%)

  

1.000

 M1

29 (63)

11 (24)

 

 M2

4 (9)

2 (4)

 

Week 12th BM blast, n (%)

  

0.548

 M1

30 (65)

13 (28)

 

 M2

3 (7)

0 (0)

 

Risk group, n (%)

  

0.385

 Intermediate risk

29 (63)

10 (22)

 

 High risk

4 (9)

3 (6)

 

Relapse, n (%)

 Yes

12 (26)

2 (4)

0.286

 No

21 (46)

11 (24)

 

Survival times

 5-years OS, cumulative survival

0.480 ± 0.08

0.846 ± 0.100

0.045

 5-years RFS,cumulative survival

0.577 ± 0.094

0.833 ± 0.108

0.155